• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·BIEL
Share

BioElectronics Corporation Stocks

$ 0Last Updated 21.10.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 7.41M

$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

BioElectronics Corporation, an electroceutical company, engages in the development and sale of wearable, neuromodulation devices to mitigate neurological diseases and enhance quality of life worldwide. Its products include ActiPatch, a musculoskeletal pain therapy; Allay, a menstrual pain therapy; and Smart Insole, a heel pain therapy. The company also offers RecoveryRx, a medical device that provides pain management therapy for medical professionals; and HealFast, a drug-free therapy for horses, cats, and dogs that reduces swelling and pain, as well as heals muscle and tendon injuries, sores, and incisions. It sells its products to wholesale distributors, hospitals and clinics, and consumers. The company was incorporated in 2000 and is headquartered in Frederick, Maryland.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is overvalued on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

22.10.2026 18:02

"Demand Is Through the Roof": Huang Identified Obstacles to Neocloud's Growth Amid Its Sell-Off

22.10.2026 17:35

An expert named six stocks you shouldn't overlook—despite Anthropic's IPO

22.10.2026 17:05

Investors seeking safe havens have driven the valuations of "toothpaste" stocks above those of the tech sector

22.10.2026 16:35

Dividends, Gold, ETFs: Wall Street Outlines 5 Steps to Protect Your Portfolio from AI Risks

22.10.2026 16:35

Nebius Secured a $3.5 Billion Credit Line Amid a Sell-Off in AI-Sector Stocks

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026